NasdaqGS:MDGLBiotechs
A Look at Madrigal Pharmaceuticals’s Valuation Following Positive Phase 3 Rezdiffra Results for MASH Cirrhosis
Madrigal Pharmaceuticals (MDGL) is drawing interest after sharing two-year results from its Phase 3 MAESTRO-NAFLD-1 trial at a major liver disease conference. The new data highlights Rezdiffra’s impact in hard-to-treat MASH cirrhosis patients.
See our latest analysis for Madrigal Pharmaceuticals.
Momentum has picked up sharply for Madrigal Pharmaceuticals, with a 30% jump in the share price over the past month and a year-to-date gain of nearly 75%. Optimism around Rezdiffra’s pivotal trial...